STOCK TITAN
  1. Home
  2. Sec-filings
  3. LKFT
  4. [6-K] Lakefront Biotherapeutics NV Current Report (Foreign Issuer)

Lakefront Biotherapeutics (LKFT) repurchases 103,970 shares in €2.41M buyback tranche

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Lakefront Biotherapeutics reported progress under its share repurchase program announced on June 9, 2026. Between August 3 and August 7, 2026, the company repurchased 103,970 ordinary shares through an independent financial intermediary at an average price of €23.18 per share, for a total consideration of €2,409,901.40. During this period, prices ranged from a low of €22.32 to a high of €23.86. As of market close on August 7, 2026, Lakefront held 808,186 of its own ordinary shares.

Positive

  • None.

Negative

  • None.
Shares repurchased 103,970 shares Repurchased between August 3 and August 7, 2026 under the buyback program
Average repurchase price €23.18 per share Average price paid for 103,970 shares during August 3–7, 2026
Total repurchase amount €2,409,901.40 Aggregate consideration for shares repurchased August 3–7, 2026
Lowest repurchase price €22.32 per share Lowest price paid during the August 3–7, 2026 repurchase period
Highest repurchase price €23.86 per share Highest price paid during the August 3–7, 2026 repurchase period
Treasury shares held 808,186 shares Own ordinary shares held as of market close on August 7, 2026
repurchase program financial
"Within the framework of the repurchase program announced on June 9, 2026"
A repurchase program is when a company buys back its own shares from the open market. This reduces the total number of shares available, which can increase the value of each remaining share and signal confidence in the company's future. For investors, it often suggests that the company believes its stock is undervalued and can be a sign of financial strength.
discretionary mandate financial
"via a discretionary mandate to an independent financial intermediary"
independent financial intermediary financial
"via a discretionary mandate to an independent financial intermediary"
forward-looking statements regulatory
"This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
Private Securities Litigation Reform Act of 1995 regulatory
"forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995"

FAQ

What did Lakefront Biotherapeutics (LKFT) announce on August 12, 2026?
Lakefront Biotherapeutics announced that it repurchased 103,970 shares of its own stock between August 3 and August 7, 2026, under its previously announced share repurchase program.

How much did Lakefront Biotherapeutics (LKFT) spend on its recent share repurchases?
Lakefront spent a total of €2,409,901.40 to repurchase 103,970 shares between August 3 and August 7, 2026, at an average price of €23.18 per share.

What price range did Lakefront Biotherapeutics (LKFT) pay for its share buybacks?
During the August 3–7, 2026 repurchase window, Lakefront paid between a low of €22.32 and a high of €23.86 per share across multiple trading venues.

How many treasury shares does Lakefront Biotherapeutics (LKFT) now hold?
As of market close on August 7, 2026, Lakefront Biotherapeutics held 808,186 of its own ordinary shares following the reported repurchases.

Under what framework were Lakefront Biotherapeutics (LKFT) shares repurchased?
The shares were repurchased under a repurchase program announced on June 9, 2026, executed via a discretionary mandate to an independent financial intermediary across several European trading venues.

On which markets did Lakefront Biotherapeutics (LKFT) execute the buybacks?
The August 3–7, 2026 buybacks were executed on multiple venues, including XAMS, CEUX, AQEU, and TQEX, via an independent financial intermediary with discretionary authority.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 6-K: How Foreign Companies Report to the SEC →
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2026

Commission File Number: 001-37384

Lakefront Biotherapeutics
(Translation of registrant's name into English)

Schaliënhoevedreef 20T, 2800 Mechelen, Belgium
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

The information contained in this Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333- 218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886, 333-283361, and 333-292050).

On August 12, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Exhibit 99.1. Press release dated August 12, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      Lakefront Biotherapeutics    
  (Registrant)
   
  
Date: August 12, 2026     /s/ Ying Deng    
  Ying Deng
  Authorized Officer
  

EXHIBIT 99.1

Acquisition of Own Shares

Mechelen, Belgium; 12 August 2026, 22.01 CET; regulated information

Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between August 3, 2026 and August 7, 2026, it has repurchased 103,970 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows:

Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€)
03/08/2026 XAMS 16,017 23.56 377,368.53 23.10 23.86
03/08/2026 CEUX 2,367 23.61 55,891.02 23.26 23.84
03/08/2026 AQEU 876 23.70 20,761.46 23.70 23.72
03/08/2026 TQEX 704 23.75 16,720.35 23.62 23.86
04/08/2026 XAMS 17,257 23.31 402,305.54 23.18 23.48
04/08/2026 CEUX 2,485 23.26 57,801.85 23.18 23.40
04/08/2026 AQEU 55 23.24 1,278.20 23.24 23.24
04/08/2026 TQEX 722 23.33 16,842.60 23.20 23.40
05/08/2026 XAMS 17,763 23.17 411,650.42 22.96 23.32
05/08/2026 CEUX 2,382 23.12 55,068.98 22.90 23.28
05/08/2026 AQEU 604 23.18 14,003.62 23.08 23.24
05/08/2026 TQEX 170 23.20 3,944.00 23.20 23.20
06/08/2026 XAMS 17,857 22.64 404,205.69 22.32 22.88
06/08/2026 CEUX 1,987 22.49 44,681.07 22.36 22.70
06/08/2026 AQEU 743 22.65 16,831.55 22.42 22.72
06/08/2026 TQEX 533 22.57 12,030.61 22.44 22.76
07/08/2026 XAMS 17,738 23.24 412,179.68 22.88 23.44
07/08/2026 CEUX 2,842 23.26 66,112.88 23.12 23.40
07/08/2026 AQEU 199 23.29 4,634.37 23.26 23.38
07/08/2026 TQEX 669 23.30 15,588.97 23.18 23.46
Total   103,970 23.18 2,409,901.40 22.32 23.86

As of market close on 07 August 2026, Lakefront holds 808,186 of its own ordinary shares.

About Lakefront Biotherapeutics
Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical‑stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class and best-in-class BCMAxCD3 T‑cell engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient impact and long‑term shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.

For further information, contact Lakefront Biotherapeutics:
Investor Relations
Sherri Spear
+1 412 522 6418
sherri.spear@lakefrontbio.com

Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,” “will,” “could,” “would,” “potential,” “forward,” “goal,” “next,” “continue,” “should,” “encouraging,” “aim,” “progress,” “remain,” “explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements regarding Lakefront’s plans to repurchase its ordinary shares. Lakefront cautions the reader that forward-looking statements are based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity, performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance, financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”), including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically required by law or regulation.

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases